XML 84 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Information (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Quarterly Financial Information Disclosure [Line Items]                    
Product revenues $ 662 $ 467 $ 969 $ 591 $ 1,466 $ 731 $ 1,126 $ 1,333 $ 2,689 $ 4,656
Gross profit 29 (20) 262 (125) 521 113 541 766 146 1,941
Development revenues 867 1,306 531 1,018 1,561 1,879 1,699 1,585    
Operating expenses (4,526) (5,629) (6,374) (6,336) (5,670) (6,789) (8,464) (7,448)    
Other expense, net (656) (464) (468) (415) (1,330) (587) (181) (242) (2,003) (2,340)
Net loss (4,286) (4,807) (6,049) (7,544) (4,918) (5,384) (6,405) (5,339) (22,686) (22,046)
Beneficial conversion feature for convertible preferred stock (3,977) 0 0 0 0 0 0 0 (3,977) 0
Net loss allocable to common stockholders $ (8,263) $ (4,807) $ (6,049) $ (7,544) $ (4,918) $ (5,384) $ (6,405) $ (5,339) $ (26,663) $ (22,046)
Basic and diluted net loss per share $ (0.20) $ (0.14) $ (0.19) $ (0.33) $ (0.24) $ (0.26) $ (0.43) $ (0.41) $ (0.82) $ (1.28)
Azaya Therapeutics, Inc. [Member]                    
Quarterly Financial Information Disclosure [Line Items]                    
In process research and development acquired from Azaya       $ (1,686)         $ (1,686) $ 0